Clinical Evidence

Tablo® is clinically effective, reliable and preferred by patients and clinicians

See latest studies

300 mL/min Qd achieves adequacy at 3x/week

Patients across a large weight range achieved adequacy targets at similar frequencies with similar treatment times doing thrice weekly hemodialysis on Tablo as compared with traditional 500 mL/min dialysate flow rates.

See analysis

Patients are more likely to try home hemodialysis with Tablo

An online survey of 202 U.S. patients with kidney failure currently treating with home hemodialysis (HHD), peritoneal dialysis (PD) or in-center dialysis (ICD) was conducted using a blinded HHD system concept that reflects the benefits and features of the Tablo system. 77% of participants on either ICD or PD responded that Tablo’s features would make them more likely to try HHD.

See poster

Patients feel better, sleep better on Tablo

As measured by the Dialysis Symptom Index (DSI), patients with ESKD on standard thrice weekly in-center dialysis reported fewer, less severe dialysis-related symptoms when converted to Tablo. Treatment time, frequency, adequacy and lab results were similar on Tablo and non-Tablo devices. Additionally, patients in the IDE trial using the Tablo system 4 days/week reported having an easier time falling asleep, staying asleep and feeling rested compared to their baseline.

See multicenter study

Qd of 300 mL/min achieves similar clearance as ≥500 mL/min

A retrospective observational study of critically ill patients requiring bedside dialysis sought to compare urea clearance between mid and conventional dialysate flow rates, and the effect of filter size in real life clinical setting.


The study found that small solute clearance, represented by URR, delivered in critically ill patients was higher in dialysis treatments with Qd of 300 vs. 600 mL/min. However, this difference was offset by the use of a larger dialyzer. These findings may have implications in hospital settings where water preservation is of priority.

See acute study

Patients can be trained on Tablo in under 2 weeks

Conversion of an HHD program to Tablo can allow shortened training time, the ability to decrease treatment frequency while achieving adequate clearance and result in favorable patient and nurse experience.


Standard facility training time prior to Tablo was 4-6 weeks. For all patients in this study, Tablo training was completed in two weeks with an average training time of 38 hours.

See poster

Nurses can be trained on Tablo in less than 4 hours

After standard Tablo training (under 4 hours), nurses of varied experience and areas of specialty reported high levels of satisfaction with their training, found Tablo easy to learn and use and were confident in treating patients independently.

The survey results affirmed general observation that the Tablo Hemodialysis System can allow training of a wide range of staff to efficiently expand a facility’s renal replacement capabilities.

See survey results

Tablo continues to demonstrate its clinical versatility, from the hospital to the home.

Latest publications

Addressing the quality of dialysis care through an insourced model

The experience of a regional acute care hospital in Oklahoma that successfully transitioned to an insourced model using the Tablo Hemodialysis System.

NKF 2025

 

Care partners report confidence in their ability to care for their loved one with little impact on their own QOL

The HOME Registry Study (NCT04526301) is a multi-center, prospective, study on patients receiving HHD with the Tablo Hemodialysis System. This interim analysis looked at the impact of Tablo training on the care partner’s perception of readiness and QOL once home assisting with treatment.

ASN 2024

 

Patients on Tablo report improvement in depressive symptoms

The HOME Registry Study (NCT04526301) is a multi-center, prospective, study on patients receiving HHD with the Tablo Hemodialysis System. The results were used to quantify the impact of Tablo home hemodialysis on participants’ mental health and perceived QOL.

ASN 2024

 

Intensive care unit improves dialysis care quality while reducing costs

A medium-sized Michigan hospital demonstrates that converting from an outsourced conventional dialysis program to an insourced PIRRT program can maintain or improve clinical outcomes in critically ill patients while reducing dialysis-related costs.

Journal of Medical Economics

 

New guidance makes it easier to dose antibiotics for critically ill patients on Tablo

Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analysis replicating KRT regimens with Tablo predicted dosing guidance for five antibiotics used with critically ill patients. Dosing regimens likely to meet therapeutic targets while minimizing toxicity risk were identified.
BMC Nephrology

 

Dialysis insourcing with Tablo led to lower mortality rates

Implementation of a new dialysis service line using Tablo decreased hospital transfers and displacement of patients in rural Alaska. CLABSI rate was 0%, and mortality and clotting event rates were slightly better than national averages.

ASN 2023

Improved symptoms of insomnia, better physical health on Tablo

The first 500 users in the Tablo HHD population were characterized and compared to data from the 2022 USRDS Annual Data Report, with early favorable trends toward diverse and equitable adoption across racial and socio-economic groups.

ASN 2023

Usability, ease of learning Tablo for patients performing HHD

Task performance from a usability validation study demonstrated effectiveness of standard Tablo training in scenarios of extended training decay (up to 28 days). 100% of participants reported confidence in using Tablo safely and effectively.

ASN 2023

Tablo HHD user study trends toward diverse, equitable adoption

The first 500 users in the Tablo HHD population were characterized and compared to data from the 2022 USRDS Annual Data Report, with early favorable trends toward diverse and equitable adoption across racial and socio-economic groups.

ASN 2023

Characteristics of Tablo HHD users in Medicare Fee-for-Service

A Medicare Advantage health plan with 500 dialysis members could reduce costs by $686 per member per month and drive $4.2 million in savings over five years by growing Tablo HHD utilization.

ASN 2023

97% treatment success among island-based HHD patients

A total of 24 patients on the islands of Maui, Oahu and Hawaii transitioned to HHD on Tablo, completing 1,893 treatments. The study found a high treatment success rate, efficient use of water and energy, and no device issues related to high humidity.

NKF SCM 2023

Tablo can make HHD accessible to rural patients

A rural clinic in Iowa found strong staff satisfaction and positive patient outcomes after making the time commitment to add this new dialysis modality to the clinic’s offerings.

NKF SCM 2023